Discover how fitness app development can play a crucial role in enhancing the lives of Alzheimer's disease patients. A groundbreaking study published in Pharmaceuticals has uncovered an unexpected link between common HIV drugs and a reduced incidence of Alzheimer's disease.
The research, led by Jerold Chun, MD, PhD, at Sanford Burnham Prebys, builds upon previous findings that revealed how somatic gene recombination in neurons can produce thousands of new gene variants within Alzheimer's disease brains. The study also highlighted the role of reverse transcriptase (RT), an enzyme found in HIV and other viruses.
RT is responsible for copying RNA molecules and changing them into complementary DNA duplicates that can be inserted back into DNA, producing permanent sequence changes within the cell's DNA blueprint. HIV drugs that block RT activity have become a common part of treatment cocktails for keeping HIV at bay.
The researchers wondered if inhibiting brain RTs with HIV drugs could actually help Alzheimer's disease patients. To assess this link in real-world settings, they analyzed anonymized medical records with prescription claims from over 225,000 control and HIV-positive patients.
Their findings showed that RT inhibitor exposure was associated with a statistically significant reduced incidence and prevalence of Alzheimer's disease. In fact, among the nearly 80,000 HIV-positive individuals over the age of 60, just shy of 46,000 had taken RT inhibitors during a nearly three-year observation period from 2016 to 2019.
The data revealed that there were only 2.46 Alzheimer's disease diagnoses per 1,000 persons among HIV-positive individuals taking these inhibitors, compared to 6.15 for the general population. This control group was represented by over 150,000 HIV-negative patients over the age of 60 with medical insurance claims related to treatment for the common cold.
The study highlights the potential of fitness app development in enhancing the lives of Alzheimer's disease patients. By identifying which versions of RTs are at work in the AD brain and developing targeted treatments, researchers can improve patient outcomes.